Table 2 Details of tumor characteristics, management, and prognosis of 12 patients with pancreatic adenosquamous carcinoma.
From: Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma
Case | Tumor location | Size (cm) | Operative method | Intraoperative irradiation | Postoperative chemotherapy | Stage* (TNM) | Survival (months) |
|---|---|---|---|---|---|---|---|
1 | Head | 6 | Biopsy, bypass | ND | ND | III (T4N1M0) | 4.04 |
2 | Head | 3.5 | PD | ND | ND | IIB (T2N1M0) | 2.50 |
3 | Body and tail | 8 | Biopsy, bypass | ND | ND | IV (T4N1M1) | 1.12 |
4 | Head | 6 | Biospy | 1,800 cGy | ND | III (T4N0M0) | 22.42 |
5 | Tail | 8 | Biopsy | 2,000 cGy | Gemcitabine | III (T4N1M0) | 5.42 |
6 | Body | 8 | Biopsy, bypass | ND | Tegafur | III (T4N1M0) | 4.41 |
7 | Head | 3.8 | PD | ND | Gemcitabine, Fluorouracil | IIB (T2N1M0) | 6.84 |
8 | Head | 5.5 | PD | ND | Gemcitabine | IIB (T3N1M0) | 6.51 |
9 | Body | 7 | subtotal P, total G, S | ND | Tegafur, Uracil | IIB (T3N1M0) | 11.84 |
10 | Tail | 5 | distal P, S | ND | ND | IIB (T2N1M0) | 10.82 |
11 | Tail | 8 | distal P, total G, S | ND | Gemcitabine, Cisplatin | IIB (T3N1M0) | 3.68 |
12 | Body and Tail | 6.5 | subtotal P, S | ND | Gemcitabine | IIB (T3N1M0) | 4.08 |